Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 1,551 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Julie Cooke sold 1,551 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the completion of the sale, the insider now directly owns 19,544 shares in the company, valued at approximately $2,282,348.32. This trade represents a 7.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Julie Cooke also recently made the following trade(s):

• On Monday, February 10th, Julie Cooke sold 700 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00.
• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Trading Down 0.9 %

Shares of NBIX traded down $1.05 during midday trading on Tuesday, reaching $113.97. The stock had a trading volume of 975,262 shares, compared to its average volume of 1,336,941. The company has a market capitalization of $11.36 billion, a price-to-earnings ratio of 34.64 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company's 50-day moving average is $137.55 and its 200 day moving average is $130.19.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. Research analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Golden State Wealth Management LLC purchased a new stake in Neurocrine Biosciences during the fourth quarter valued at about $25,000. Huntington National Bank lifted its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after acquiring an additional 97 shares during the last quarter. Brooklyn Investment Group boosted its holdings in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after acquiring an additional 115 shares during the period. GeoWealth Management LLC grew its position in Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after buying an additional 220 shares during the period. Institutional investors own 92.59% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price target for the company. Canaccord Genuity Group reduced their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating for the company in a report on Friday, February 7th. Morgan Stanley increased their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Barclays raised their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday, December 23rd. Finally, Royal Bank of Canada decreased their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.